Opendata, web and dolomites

FutureTrophicFactors SIGNED

Elucidating therapeutic effects and mode of action of future trophic factorsin ALS and Parkinson’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FutureTrophicFactors project word cloud

Explore the words cloud of the FutureTrophicFactors project. It provides you a very rough idea of what is the project "FutureTrophicFactors" about.

blood    trials    neurite    peripheral    da    branching    fragment    data    showed    groundbreaking    relieve    population    peptides    protein    vitro    prevalence    survival    overcome    drawbacks    aging    neurorestorative    human    amyotrophic    treatments    discovery    protects    ips    progression    disease    measured    regulate    cell    culture    nerve    therapies    neurotrophic    penetrating    rodent    ntfs    diseases    ntf    rhesus    clinical    ultimate    neurodegenerative    life    model    pass    innovative    treatment    patients    explored    understand    difficulty    effect    animal    invasive    cultures    barrier    function    pd    treating    models    direct    cells    cdnf    variant    brain    poor    mode    symptoms    bbb    polypeptides    lateral    drugs    surgery    vivo    ohda    als    motor    restores    secretary    despite    efficacy    expectancy    subcutaneously    dopamine    pluripotent    toxin    stop    monkey    trophic    neurons    action    proteins    urgent    stem    therapeutic    enters    sclerosis    parkinson    administered    treat   

Project "FutureTrophicFactors" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 1˙497˙597 €
 EC max contribution 1˙497˙597 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 1˙497˙597.00

Map

 Project objective

The prevalence of neurodegenerative diseases such as Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) is growing rapidly due to an aging population and increased life expectancy. Current treatments for ALS and PD only relieve symptoms and cannot stop the progression of the disease, thus there is an urgent need for new therapies. Neurotrophic factors (NTFs) are secretary proteins that regulate the survival of neurons, neurite growth and branching. They have been explored as novel drugs for the treatment of ALS and PD but their efficacy in clinical trials is poor. CDNF is a protein with NTF properties that protects and restores the function of dopamine neurons in rodent and rhesus monkey toxin models of PD more effectively than other NTFs. CDNF is currently in phase 1/2 clinical trials on PD patients. Despite promising results with CDNF in animal models of PD, NTF and CDNF-based treatments have drawbacks. CDNF requires direct delivery to the brain through invasive surgery since, it cannot pass through the blood brain barrier (BBB). My recent discovery, however, may overcome this difficulty: I showed that a novel CDNF variant protects DA neurons in vitro and in vivo and that it efficiently enters DA neurons in culture. Furthermore, my data show the CDNF fragment can pass through the BBB as measured by 3 different methods and has a neurorestorative effect in a 6-OHDA toxin model of PD when administered subcutaneously. The ultimate goal of my research is to understand the mode of action and therapeutic effect of novel BBB penetrating CDNF-derived polypeptides in cultures of human induced pluripotent stem (iPS) cell-derived nerve cells from patients and in animal models of ALS and PD. The innovative aspect of this proposal is the new groundbreaking concept for treating neurodegenerative diseases – peripheral delivery of BBB penetrating peptides with trophic factor properties and the potential to treat non-motor and motor symptoms in ALS and PD patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUTURETROPHICFACTORS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUTURETROPHICFACTORS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

Resonances (2019)

Resonances and Zeta Functions in Smooth Ergodic Theory and Geometry

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More